Overall, studies have observed encouraging therapeutic potential of liver-specific ROCK1 inhibition in metabolic disease models, demonstrated by increased energy expenditure, improved insulin sensitivity, and attenuated lipid accumulation. The gene discussed is INS; the disease is metabolic disease.